Flow cytometry method for the analysis of membrane-associated human chorionic gonadotropin, its subunits, and fragments on human cancer cells.
A quantitative flow cytometry method for the analysis of membrane-associated human chorionic gonadotropin (hCG), its subunits, and fragments on human cancer cells was developed using a double-antibody reaction; a flow cytometry with a 2-W argon laser, standard settings, and filters for fluorescein isothiocyanate use; commercially available software; and the ectopic hCG producer CCL 2 HeLa cells from the American Type Culture Collection (ATCC) as a cell control to standardize the reagents and for overall quality control. Twenty-two monoclonal antibodies (MoAb) and immunoglobulin G fractions from three rabbit polyclonal antisera were tested for effects of antibody concentration (titration), reproducibility at different levels of epitope expression, and variability of epitope expression to select appropriate primary antibodies. Based on the results of the various tests, three polyclonal immunoglobulin G antibodies and a panel of nine MoAb directed to epitopes located in five different regions on the hCG molecule were selected as first antibodies. Their specificity was determined by using two unrelated MoAb of the same isotype at the same concentration to replace the primary MoAb and by a competition experiment. The unrelated MoAb also were used for the selection of the appropriate control fluorescence profile needed for the software. The unique characteristics of this method were: the use of living cells, standardized reagents, internal and external quality control, and the highest sensitivity, which could detect as few as 10(3) molecules of fluorochrome per cell. Serial analyses of the ATCC CCL 2 HeLa cells and two of its variants and of the eutopic hCG producer JEG-3 choriocarcinoma cells revealed the expression of membrane-associated epitopes of intact hCG, its subunits, and fragments by a high percentage of the cells, indicating that the expression of these sialoglycoproteins by these two different types of cancer cells is a common phenotypic characteristic.
Acevedo
H F
HF
Department of Pathology and Laboratory Medicine, Allegheny General Hospital, Pittsburgh, PA 15212.
Krichevsky
A
A
Campbell-Acevedo
E A
EA
Galyon
J C
JC
Buffo
M J
MJ
Hartsock
R J
RJ
D000230:Adenocarcinoma / Q000737:chemistry* / Q000473:pathology; D000911:Antibodies, Monoclonal; D001667:Binding, Competitive; D002462:Cell Membrane / Q000502:physiology; D002470:Cell Survival / Q000502:physiology; D006063:Chorionic Gonadotropin / Q000032:analysis* / Q000276:immunology / Q000502:physiology; D000939:Epitopes / Q000032:analysis / Q000276:immunology; D005260:Female; D005434:Flow Cytometry / Q000379:methods*; D006367:HeLa Cells; D006801:Humans; D009369:Neoplasms / Q000737:chemistry* / Q000473:pathology; D010446:Peptide Fragments / Q000032:analysis*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013997:Time Factors
D000911:Antibodies, Monoclonal; D006063:Chorionic Gonadotropin; D000939:Epitopes; D010446:Peptide Fragments